Quarterly report pursuant to Section 13 or 15(d)

CONDENSED BALANCE SHEETS

v3.19.3
CONDENSED BALANCE SHEETS - USD ($)
$ in Thousands
Sep. 30, 2019
Dec. 31, 2018
Current assets:    
Cash and cash equivalents $ 921 $ 9,295
Restricted cash 0 361
Receivables 775 1,737
Inventory 1,309 1,262
Contract assets 0 99
Prepaid expenses and other current assets 941 547
Total current assets 3,946 13,301
Property and equipment, net 752 794
Operating lease right-of-use asset 456 0
Deferred offering costs 150 0
Total assets 5,304 14,095
Current liabilities:    
Accounts payable 1,383 1,526
Accrued clinical trials expenses 434 620
Accrued sales allowances 750 0
Other accrued liabilities 653 466
Deferred revenue 0 313
Operating lease liability, current 262 0
Current portion of long-term debt 0 527
Total current liabilities 3,482 3,452
Operating lease liability, non-current 222 0
Long-term debt 3,872 3,787
Warrant liability 388 0
Derivative liability 0 25
Total liabilities 7,964 7,264
Stockholders' (deficit) equity:    
Common stock, $0.001 par value per share: 125,000 shares authorized; 17,114 and 13,010 shares issued and outstanding at September 30, 2019 and December 31, 2018 17 13
Additional paid-in capital 342,419 339,397
Accumulated deficit (345,096) (332,579)
Total stockholders' (deficit) equity (2,660) 6,831
Total liabilities and stockholders' (deficit) equity $ 5,304 $ 14,095